Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all (Q24609011)

From Wikidata

Revision as of 22:15, 28 November 2018 by Citationgraph bot (talk | contribs) (‎Updated Item: Updating citation graph)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all	scientific article

Statements

scholarly article

0 references

Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all (English)

0 references

0 references

author name string

Awewura Kwara

1

0 references

Geetha Ramachandran

2

0 references

Soumya Swaminathan

3

0 references

language of work or name

0 references

publication date

January 2010

0 references

Expert Opinion on Drug Metabolism & Toxicology

0 references

6

0 references

1

0 references

55-68

0 references

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

7 April 2017

Optimizing pediatric dosing: a developmental pharmacologic approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Immune reconstitution disease associated with mycobacterial infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Children with HIV are not small adults: what is different in pharmacology?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: Pharmacogenetic effect of CYP2B6 variation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Antiretroviral pharmacokinetic profile: a review of sex differences

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Drug metabolism and variability among patients in drug response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Issues in the management of HIV-related tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Induction of phase I, II and III drug metabolism/transport by xenobiotics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Practical guidelines to interpret plasma concentrations of antiretroviral drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

27 September 2017

Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

30 May 2018

A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

30 May 2018

Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

30 May 2018

Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

30 May 2018

Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

30 May 2018

Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005.

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Pharmacokinetic interactions between efavirenz and rifampicin in the treatment of HIV and tuberculosis: one size does not fit all.

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 weeks results

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Safety and antiretroviral effectiveness of concomitant use of rifampicin and efavirenz for antiretroviral-naive patients in India who are coinfected with tuberculosis and HIV-1.

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

High prevalence of the CYP2B6 516G-->T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Pharmacokinetic interaction between nevirapine and rifampicin in HIV-infected patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Co-administration of rifampin and nevirapine in HIV-infected patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Association of high T allele frequency of CYP2B6 G516T polymorphism among ethnic south Indian HIV-infected patients with elevated plasma efavirenz and nevirapine

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

Antiretroviral Concentrations in Untimed Plasma Samples Predict Therapy Outcome in a Population with Advanced Disease

1 reference

https://api.crossref.org/works/10.1517%2F17425250903393752

21 January 2018

A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

28 November 2018

Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

28 November 2018

Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

28 November 2018

Study of ABCB1 polymorphism (C3435T) in HIV-1-infected individuals from South India

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

28 November 2018

Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

28 November 2018

Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

28 November 2018

Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

28 November 2018

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

28 November 2018

Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

28 November 2018

Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

28 November 2018

Disposition and biotransformation of the antiretroviral drug nevirapine in humans.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2939445

28 November 2018

Identifiers

10.1517/17425250903393752

0 references

PMC publication ID

0 references

PubMed publication ID

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24609011&oldid=801212081"